-
Sun Pharma vs Dr Reddy’s 2027: Profits Fell Over 30% at Both, Yet One Stock Sits Near Its 52-Week High
- November 20, 2026
- Posted by: Kunal Singla
- Category: Market
No Comments
Sun Pharma vs Dr Reddy’s 2027: both reported Q2 FY27 profit declines of more than 30%, but Dr Reddy’s trades within 1% of its 52-week high while Sun Pharma is about 7% below. A side-by-side data comparison.
-
Aurobindo Pharma Analyst Review 2027: Record Quarter Lifts Targets Near ₹2,110
- November 20, 2026
- Posted by: Kunal Singla
- Category: Market
Aurobindo Pharma posted a record Q2 FY27 with profit up about 33% to ₹1,124 crore, helped by Lannett, Europe and broad formulation growth. Geojit and Motilal Oswal set targets near ₹2,110 while Prabhudas Lilladher holds at ₹1,775. We review results, targets and risks for 2027.
-
AstraZeneca Pharma India Analyst Review 2027: Sales Jump 30% but Profit Lags and P/E Stays Near 86
- November 20, 2026
- Posted by: Chaitanya Auti
- Category: Market
AstraZeneca Pharma India grew Q2 FY27 revenue 30% to ₹729 crore, helped by oncology and a fast-growing rare disease business, but net profit rose only 15%. With thin brokerage coverage and a P/E near 86, we review results, valuation and risks for 2027.
-
3 Cancer Medicines Maker, Heritage Resorts Owner and Gas Field Operator Stocks With a Strong Future Roadmap: Emcure Pharmaceuticals, Chalet Hotels and Oil and Natural Gas Corporation
- November 19, 2026
- Posted by: Chaitanya Auti
- Category: Best Stocks
Oncology Generic, Resort and Gas Well Stocks with a strong future roadmap: Emcure Pharmaceuticals, Chalet Hotels and Oil and Natural Gas Corporation. Compare price, valuation, return on equity and revenue growth as of 17 November 2026.
-
Alpa Laboratories Analyst Review 2027: Sales Rise 10% but Q2 Swings to a Loss
- November 19, 2026
- Posted by: Chaitanya Auti
- Category: Market
Alpa Laboratories grew Q2 FY27 sales about 10% to ₹32.22 crore but posted a loss of ₹1.85 crore as operating profit turned negative. The Indore drug maker trades at about 0.58 times book, near its 52-week low. With no brokerage coverage, we review results and risks.
-
Albert David Analyst Review 2027: Sales Up 16% and Margins Recover, Profit Back in Black
- November 19, 2026
- Posted by: Ankit Jaiswal
- Category: Market
Albert David grew Q2 FY27 sales 16% to ₹100.83 crore and returned to a ₹2.88 crore profit after a loss a year ago, as operating margin rose to 11.6%. The Kolkata drug maker trades near book value. With no brokerage coverage, we review results, the business and risks.
-
Alpa Laboratories Analyst Review 2027: Sales Rise 10% but Q2 Swings to a Loss
- November 19, 2026
- Posted by: Chaitanya Auti
- Category: Market
Alpa Laboratories grew Q2 FY27 sales about 10% to ₹32.22 crore but posted a loss of ₹1.85 crore as operating profit turned negative. The Indore drug maker trades at about 0.58 times book, near its 52-week low. With no brokerage coverage, we review results and risks.
-
Albert David Analyst Review 2027: Sales Up 16% and Margins Recover, Profit Back in Black
- November 19, 2026
- Posted by: Ankit Jaiswal
- Category: Market
Albert David grew Q2 FY27 sales 16% to ₹100.83 crore and returned to a ₹2.88 crore profit after a loss a year ago, as operating margin rose to 11.6%. The Kolkata drug maker trades near book value. With no brokerage coverage, we review results, the business and risks.
-
Alembic Pharma Analyst Review 2027: Profit Up 81% and Guidance Raised, Stock Runs Past Targets
- November 19, 2026
- Posted by: Chaitanya Auti
- Category: Market
Alembic Pharma grew Q2 FY27 revenue 36% and profit 81% to ₹335 crore, led by a 77% jump in US sales, and raised FY27 growth guidance to 20% to 25%. The stock has run past Motilal Oswal’s ₹845 target. We review results, segments, valuation and risks.
-
Ajanta Pharma Analyst Review 2027: Profit Up 49% as Brokers Split Between ₹3,908 and ₹4,250
- November 19, 2026
- Posted by: Chaitanya Auti
- Category: Market
Ajanta Pharma grew Q2 FY27 revenue about 33% to ₹1,794 crore and profit about 49% to ₹388 crore, beating its margin guidance. PL Capital raised its target to ₹4,250 while Systematix moved to Hold. We review results, segments, valuation and risks.
- 1
- 2